FY4/24 2Q
Supplementary Materials

December 6, 2023

１．Consolidated Results■Year-on-Year(¥ million)

FY4/23 2Q
results

FY4/24 2Q
results

Net sales

171,204

193,727+22,523+13.2

Gross profit

24,98927,767+2,778+11.1% of net sales

14.6

14.3

18,202

19,017+815

+4.5

10.6

9.8

6,786

8,749

+1,963

+28.9

4.0

4.5

7,285

9,338

+2,053

+28.2

4.3

4.8

3,805

5,257

+1,452+38.2% of net sales

2.2

2.7

Earnings pershare(¥)

108.32149.66+41.34+38.2

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

Profit attributableto owners of parent

YoYchange

YoYchange(%)

Figures in the table are rounded down
FY4/23 2Q: Reflect finalized figures of provisional accounting treatment related to business combination■Vs Plan(¥ million)

FY4/24 2Q
plan

FY4/24 2Q
results

Net sales

183,459

193,727+10,268+5.6

Gross profit

25,546

27,767+2,221+8.7% of net sales

13.9

14.3

19,45919,017(442)

(2.3)

10.6

9.8

6,087

8,749

+2,662+43.73.3

4.5

6,421

9,338+2,917+45.4

3.5

4.8

3,185

5,257+2,072+65.1% of net sales

1.7

2.7

Earnings pershare(¥)

90.66

149.66+59.00+65.1

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

Profit attributableto owners of parent

Figures in the table are rounded down

-1-

Vs planchangeVs planchange(%)

２. Segment Information（Dispensing Pharmacy Business）■Year-on-Year(¥ million)

FY4/23 2Q
results

FY4/24 2Q
results

Net sales

153,248

173,234+19,986+13.0

Gross profit

18,33820,144+1,806+9.8% of net sales

12.0

11.6

8,001

8,204+203+2.5

5.2

4.7

10,336

11,939+1,603+15.5

6.7

6.9

10,771

12,492+1,721

+16.0

7.0

7.2

SG&A expenses% of net sales

Operating profit% of net sales

Segment profit% of net sales

YoYchange

YoYchange(%)

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income
FY4/23 2Q: Reflect finalized figures of provisional accounting treatment related to business combination■Vs Plan(¥ million)

FY4/24 2Qplan

FY4/24 2Q
results

Net sales

164,380

173,234+8,854+5.4

Gross profit

18,40020,144+1,744+9.5% of net sales

11.2

11.6

8,340

8,204(136)

(1.6)

5.1

4.7

10,06011,939+1,879+18.7

6.1

6.9

10,40012,492+2,092+20.1

6.3

7.2

SG&A expenses% of net sales

Operating profit% of net sales

Segment profit% of net sales

Vs planchange

Vs planchange(%)

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income-2-3. Segment Information（Cosmetic and Drug Store Business）■Year-on-Year(¥ million)

FY4/23 2Q
results

FY4/24 2Qresults

Net sales

12,205

14,832+2,627+21.5

Gross profit

4,562

5,674+1,112+24.4% of net sales

37.4

38.3

4,244

4,363+119+2.8% of net sales

34.8

29.4

Operating profit

317

1,311+994+313.6% of net sales

2.6

8.8

Segment profit349

1,318+969+277.7% of net sales

2.98.9

SG&A expenses

YoYchange

YoYchange(%)

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income■Vs Plan(¥ million)

FY4/24 2Q
plan

FY4/24 2Q
results

Net sales

13,438

14,832+1,394+10.4

Gross profit

5,101

5,674+573+11.2% of net sales

38.0

38.3

4,551

4,363(188)(4.1)% of net sales

33.9

29.4

Operating profit

550

1,311+761+138.4% of net sales

4.1

8.8

Segment profit

550

1,318+768+139.6% of net sales

4.1

8.9

SG&A expenses

Vs planchange

Vs planchange(%)

Figures in the table are rounded down
Segment profit is adjusted to ordinary profit shown on the quarterly consolidated statement of income-3-4. Sales Verification■Dispensing Pharmacy Business (YoY）■Dispensing Pharmacy Business（Vs Plan）

Net sales

Net sales（%）

Average
Prescription
prescription
volume（%）
price

Average
Prescription
prescription
volumeprice

Same store (1,068)＋7.7＋5.7＋1.9

Same store (1,068)＋5.6＋3.7＋1.9

Store openings in theprevious year (134)＋98.1＋84.0＋8.5

Store openings in theprevious year (134)＋7.2＋3.9＋3.3

Total (1,217)＋13.3＋10.6＋2.5

Total (1,217)＋5.5＋3.6＋1.9

YoY:FY4/23 2Q Reflect finalized figures of provisional accounting treatment related to business combination■Cosmetic and Drug Store Business（YoY）（%）

Net sales

Number ofcustomers

Averagespending per
customer■Cosmetic and Drug Store Business (Vs Plan）（%）

Net sales

Average
Number ofspending per
customers
customerSame store (68)＋24.2

＋13.8＋9.2

Same store (68)＋8.1(2.6)＋11.0Store openings in theprevious year (8)＋283.0＋282.4＋0.1

Store openings in theprevious year (8)

＋11.5

＋9.0

＋2.3

＋21.5

＋12.7＋7.8

Total (78)＋10.4(2.2)＋12.9

Total (78)-4-5. Consolidated Balance Sheet■Assets(¥ million)

End-FY4/23 2Q

End-FY4/23

End-FY4/24 2Q

Change46,723
12,147
21,44098,28819,983
10,585

46,796
13,24921,58698,305
21,407
10,60250,51813,64324,855108,214
23,624
10,313+3,722+394+3,269+9,909+2,217(289)36,90339,45940,677+1,21848,49153,8202,811
6,124
23,07046,44352,343
2,720
5,990
24,507

44,63450,9762,900
6,046
25,213(1,809)(1,367)+180+56+706

42,28741,64143,054+1,413

Total assets

133,011231,299

133,444
231,750

134,708
242,922+1,264+11,172

Figures in the table are rounded down

Change: End-FY4/24 2Q compared with end-FY4/23

Cash on hand and in banks
Accounts receivable
Inventories
Total current assets
Buildings and structures, net
Land
Total property, plant andequipment
Goodwill
Total intangible fixed assets
Investments in securities
Deferred tax assets
Deposits and guarantees
Total investments and otherassets
Total fixed assets

Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees)
totaled ¥6,196million
End-FY4/23 2Q: Reflect finalized figures of provisional accounting treatment related to business combination■Liabilities and Net Assets

End-FY4/23 2Q

End-FY4/23

End-FY4/24 2Q

ChangeTotal liabilities and net assets

60,7193,776
93,30910,03817,120110,429
21,89420,50480,534
120,933
120,869
231,299

58,6983,670
92,986
5,021
12,218105,204
21,89420,50485,963
126,362
126,546
231,750

66,556
3,643
102,718
2,996
10,359113,078
21,894
20,49989,113
129,524
129,844
242,922+7,858(27)+9,732(2,025)(1,859)+7,874(5)+3,150+3,162+3,298+11,172

Figures in the table are rounded down

Change: End-FY4/24 2Q compared with end-FY4/23(¥ million)
Accounts payable
Short-term debt
Total current liabilities
Long-term debt
Total long-term liabilities
Total liabilities
Common stock
Capital surplus
Retained earnings
Total shareholdersʼ equity
Total net assets

End-FY4/23 2Q: Reflect finalized figures of provisional accounting treatment related to business combination-5-6. FY4/24 Plan (Consolidated)

Net sales

358,742

375,000

390,263

+8.8

+4.1

Gross profit

53,69855,413

58,106

＋8.2

＋4.9

15.0

14.8

14.9

37,69439,75039,656＋5.2(0.2)

10.5

10.6

10.2

16,004

15,66318,450

+15.3

＋17.8

4.5

4.2

4.7

17,06416,302

19,340

+13.3

＋18.6

4.8

4.3

5.0

Profit attributableto owners of parent

9,234

8,250

10,000+8.3＋21.2% of net sales

2.6

2.2

2.6

Earnings pershare(¥)

262.87234.84284.64

+8.3

＋21.2

Annual dividend (¥)

60.00

60.00

60.00

0.0

0.0

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

FY4/24
revised plan

Vs initialplan change（%）(¥ million)% of net sales

FY4/24
initial plan

YoYchange（%）

FY4/23
results

Figures in the table are rounded down-6-7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22 FY4/23

FY4/242Q

Organic

32272523141525279M&A1101821113461424114

6Total

881

1,066

1,029

1,132

1,088

1,065

1,099

1,2091,217■Number of Store Openings in Cosmetic and Drug Store Business
FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22 FY4/23

FY4/242Q

Organic

594715111282Total

525248546369787878

Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/corporate/
This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared for
information purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-